With €16.8 Billion in Cash and a Pipeline to Prove, BioNTech Faces ASCO's Verdict

BioNTech shares lag 22% below 52-week high despite €16.8B cash and promising oncology pipeline. ASCO oral presentations on Pumitamig and Gotistobart could unlock consensus target of $125.45.

BioNTech’s stock closed Friday at €79.50, roughly 22% below its 52-week high and barely a tenth above the cycle low of €72.50. The divergence could not be starker: while the Mainz-based biotech is barrelling into the American Society of Clinical Oncology (ASCO) annual meeting in Chicago with a deep oncology pipeline, the market has punished the shares by more than 15% over the past month. The 200-day moving average of €86.47 sits untouched above current levels, and the relative strength index at 50.6 points to a market that has yet to pick a directional bet.

That disconnect is not lost on sell-side analysts. Bernstein initiated coverage with a Market Perform rating and a $96 price target, acknowledging BioNTech’s fortress balance sheet — roughly €16.8 billion in cash at the end of the first quarter — while flagging elevated pipeline approval risk. J.P. Morgan shortly before reaffirmed its Hold rating. Yet the broader consensus from 17 analysts stands at Buy, with an average target of $125.45, implying a 38% upside from Friday’s close.

The catalysts that could close that gap will be on full display from May 29 to June 2 in Chicago. Two oral presentations will feature BioNTech’s key oncology candidates: Pumitamig and Gotistobart. These are not early-stage experiments; both are generating what the company describes as consistent positive signals across multiple tumor types.

Pumitamig, a bispecific immunomodulator that combines PD-L1 inhibition with VEGF-A neutralization, has already produced encouraging data in small-cell lung cancer and triple-negative breast cancer. The third dataset comes from the phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer, where it is being tested alongside chemotherapy. A head-to-head phase 3 study against the standard pembrolizumab-plus-chemo regimen is already running.

Gotistobart, a CTLA-4 antibody designed to selectively deplete regulatory T-cells, is being evaluated in the phase 2 PRESERVE-004 trial for platinum-resistant ovarian cancer. Here it is combined with pembrolizumab in a chemotherapy-free regimen that aligns with BioNTech’s long-term ambition to eliminate chemo from treatment protocols. Earlier data in lung cancer tested Gotistobart as a monotherapy; the combination approach is the new strategic focus.

The financial muscle to sustain this pipeline is considerable. BioNTech’s research spending hit €557 million in the first quarter alone, and the company is running more than 25 phase 2 and phase 3 studies, including 13 that are potentially pivotal. This year it plans to launch an additional six phase 3 trials, bringing the total to 15, and expects to release seven late-stage data packages by year-end. The 2026 revenue forecast stands at $2.3 billion to $2.6 billion, a target the company recently reaffirmed.

For now, the market is looking for proof that the oncology franchise can fill the void left by shrinking Covid vaccine sales. The ASCO presentations — two of the most closely watched data reads in BioNTech’s recent history — are the next tangible test. If Pumitamig and Gotistobart deliver, the 38% gap between the current price and the analyst consensus may begin to close.